CDK10 and hepatocellular carcinoma: Hypermethylation of CDK10 promoter was also confirmed with high frequency (57.5%) of nasopharyngeal carcinomas samples and cell lines and low CDK10 expression is also correlating with advanced TNM stages in HCC samples where its expression could regulate chemosensitivity to cisplatin and epidoxorubicin.392,396